Immix Biopharma, Inc. IMMX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.09M-122% | -$10.65M-121% | -$7.59M-6.1% | -$6.62M-50.3% | -$4.54M+14.8% | ||
| $91.58K+140% | $52.11K+153% | $96.99K+1,680% | $58.49K+1,408% | $38.15K+1,168% | ||
| $575.57K-33.7% | $570.8K-19.1% | $470.47K-35.9% | $532.25K-16.6% | $868.36K-7.9% | ||
| -$34.15K— | —— | —— | —— | —— | ||
| $432.21K+67.1% | —— | $1.04M-48.3% | $524.19K— | $258.72K-86.6% | ||
| $866.6K+174% | $191.35K+135% | —— | —— | $316.62K-33.6% | ||
| $725+100% | -$12.38K-106% | -$21.56K— | -$21.98K— | -$2M-320% | ||
| -$35.23K-123% | -$33.37K— | -$32.67K— | -$16.14K— | -$15.83K-174% | ||
| -$9.83M-483% | -$11.03M-647% | -$5.91M-46.3% | -$5.31M-1.0% | -$1.69M+56.0% | ||
| $32.49K-52.0% | $165.13K-67.4% | $372.46K+37.2% | $127.63K+31.5% | $67.71K-77.6% | ||
| $7.77M+379% | $1.62M— | $1.62M— | $1.62M— | $1.62M— | ||
| $3M— | —— | —— | —— | —— | ||
| -$4.8M-6,990% | -$6.65M-1,210% | -$372.46K-37.2% | -$127.63K-31.5% | -$67.71K+77.6% | ||
| $33.53K— | $95.51M— | $10.77M— | —— | —— | ||
| $71.09K+108% | $34.25K— | $34.25K— | $34.25K— | $34.25K— | ||
| -$37.56K— | $95.67M— | $10.61M— | —— | —— | ||
| -$12.81K-60.2% | —— | —— | $44.14K— | -$8K+22.8% | ||
| -$14.68M-734% | $77.98M— | $4.31M— | -$4.28M— | -$1.76M-115% | ||
| —— | —— | $7.72K-30.7% | $8.91K-13.2% | $9.82K+11.1% | ||
| $91.58K+140% | $52.11K+153% | $96.99K+1,680% | $58.49K+1,408% | $38.15K+1,168% | ||
| $725+100% | -$12.38K-106% | -$21.56K— | -$21.98K— | -$2M-320% | ||
| -$35.23K-123% | -$33.37K— | -$32.67K— | -$16.14K— | -$15.83K-174% | ||
| $432.21K+67.1% | —— | $1.04M-48.3% | $524.19K— | $258.72K-86.6% | ||
| $866.6K+174% | $191.35K+135% | —— | —— | $316.62K-33.6% | ||
| $7.77M+379% | $1.62M— | $1.62M— | $1.62M— | $1.62M— | ||
| $3M— | —— | —— | —— | —— | ||
| —— | $31.2K— | $31.2K— | $31.2K— | $31.2K— | ||
| $10.65K— | —— | —— | —— | —— | ||
| $39.19K+86.4% | $38.52K+85.8% | $37.87K+85.1% | $21.34K+4.5% | $21.03K+0.9% | ||
| -$35.23K-123% | -$33.37K— | -$32.67K— | -$16.14K— | -$15.83K-174% | ||
| $3— | —— | —— | —— | —— | ||
| —— | —— | $7.72K-30.7% | $8.91K-13.2% | $9.82K+11.1% | ||
| —— | $49.83K— | —— | $38.45K— | $354.23K+2,915% | ||
| —— | —— | —— | —— | $16— | ||
| -$9.86M-462% | -$11.19M-464% | -$6.28M-45.7% | -$5.44M-1.6% | -$1.75M+57.5% | ||
| -$9.86M-462% | -$11.19M-464% | -$6.28M-45.7% | -$5.44M-1.6% | -$1.75M+57.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Immix Biopharma, Inc. generate?
- Immix Biopharma, Inc. (IMMX) generated -$32.1M in operating cash flow over the trailing twelve months.
- What is Immix Biopharma, Inc.'s free cash flow?
- After $697.7K of capital expenditures, Immix Biopharma, Inc.'s free cash flow was -$32.8M over the trailing twelve months, down 144.6% year over year.
- Where does Immix Biopharma, Inc.'s cash flow data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.